Xeris Biopharma Holdings, Inc. (XERS)
8.465
-0.14
(-1.57%)
USD |
NASDAQ |
Aug 28, 14:25
Xeris Biopharma Holdings Cash from Operations (Quarterly) : 8.263M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.263M |
| March 31, 2026 | 9.87M |
| December 31, 2025 | 20.04M |
| September 30, 2025 | 18.43M |
| June 30, 2025 | 0.182M |
| March 31, 2025 | -10.03M |
| December 31, 2024 | 1.975M |
| September 30, 2024 | -8.305M |
| June 30, 2024 | -10.35M |
| March 31, 2024 | -20.30M |
| December 31, 2023 | 6.286M |
| September 30, 2023 | -14.61M |
| June 30, 2023 | -13.74M |
| March 31, 2023 | -26.14M |
| December 31, 2022 | -16.12M |
| September 30, 2022 | -17.75M |
| June 30, 2022 | -20.61M |
| March 31, 2022 | -48.41M |
| December 31, 2021 | -28.95M |
| Date | Value |
|---|---|
| September 30, 2021 | -22.61M |
| June 30, 2021 | -20.02M |
| March 31, 2021 | -23.96M |
| December 31, 2020 | -10.87M |
| September 30, 2020 | -16.98M |
| June 30, 2020 | -23.76M |
| March 31, 2020 | -28.94M |
| December 31, 2019 | -29.57M |
| September 30, 2019 | -30.58M |
| June 30, 2019 | -23.04M |
| March 31, 2019 | -21.15M |
| December 31, 2018 | -18.34M |
| September 30, 2018 | -15.92M |
| June 30, 2018 | -14.22M |
| March 31, 2018 | -7.805M |
| December 31, 2017 | -9.10M |
| September 30, 2017 | -5.577M |
| June 30, 2017 | -6.467M |
| March 31, 2017 | -3.519M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Zevra Therapeutics, Inc. | 17.03M |
| Aclaris Therapeutics, Inc. | -19.85M |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 33.54M |
| Veru, Inc. | -5.467M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.209M |
| Cash from Financing (Quarterly) | 1.943M |
| Free Cash Flow | 55.67M |
| Free Cash Flow Per Share (Quarterly) | 0.0466 |
| Free Cash Flow to Equity (Quarterly) | -22.84M |
| Free Cash Flow to Firm (Quarterly) | 15.00M |
| Free Cash Flow Yield | 3.71% |